A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Actym Therapeutics, Inc.
NGM Biopharmaceuticals, Inc
Prelude Therapeutics
Pfizer
NGM Biopharmaceuticals, Inc
Centre Hospitalier Universitaire Vaudois
Candel Therapeutics, Inc.
Quadriga Biosciences, Inc.
Xencor, Inc.
A&G Pharmaceutical Inc.
Eli Lilly and Company
MacroGenics
Abramson Cancer Center at Penn Medicine
Masonic Cancer Center, University of Minnesota
Valerio Therapeutics
Valerio Therapeutics
University of Chicago
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)